Purple Biotech LTD. (PPBT) — SEC Filings

Overview

Purple Biotech LTD. (PPBT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 23, 2026: Purple Biotech Ltd. announced on April 23, 2026, the establishment of a Scientific Advisory Board (SAB) to bolster the development of its C-series drug candidates. The SAB will comprise leading experts in the field, aiming to accelerate the company's research and development efforts.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 11 bullish, 39 neutral. The dominant filing sentiment for Purple Biotech LTD. is neutral.

Filing Type Overview

Purple Biotech LTD. (PPBT) has filed 48 6-K, 1 20-F, 1 SC 13G/A with the SEC between Sep 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Purple Biotech Forms Scientific Advisory Board — 6-K · Apr 23, 2026 Risk: low
  Purple Biotech Ltd. announced on April 23, 2026, the establishment of a Scientific Advisory Board (SAB) to bolster the development of its C-series drug candidat
• Purple Biotech Partners with Converge Bio for AI Oncology Acceleration — 6-K · Mar 25, 2026
  Purple Biotech Ltd. announced on March 25, 2026, a new AI collaboration with Converge Bio aimed at accelerating the development of their oncology pipeline. This
• Purple Biotech Ltd. Holds Shareholder Meeting — 6-K · Dec 16, 2025 Risk: low
  Purple Biotech Ltd. announced the results of its Extraordinary General Meeting of Shareholders held on December 15, 2025. The meeting took place at the Company'
• 6-K Filing — 6-K · Dec 11, 2025
• Purple Biotech Ltd. Updates Corporate Presentation — 6-K · Nov 19, 2025 Risk: low
  On November 19, 2025, Purple Biotech Ltd. released an updated corporate presentation titled "Purple Biotech Corporate Presentation November 2025". This filing i
• 6-K Filing — 6-K · Nov 14, 2025
• Purple Biotech Hits Manufacturing Milestone for IM1240 — 6-K · Oct 29, 2025 Risk: medium
  On October 29, 2025, Purple Biotech Ltd. announced a significant manufacturing milestone for IM1240, a tri-specific antibody developed on their CAPTN-3 platform
• Purple Biotech Schedules Shareholder Meeting for December 15 — 6-K · Oct 28, 2025 Risk: low
  Purple Biotech Ltd. announced on October 28, 2025, that an Extraordinary General Meeting of Shareholders will take place on December 15, 2025, at 4:30 p.m. Isra
• Purple Biotech Receives Nasdaq Minimum Bid Price Notification — 6-K · Oct 20, 2025 Risk: medium
  On October 20, 2025, Purple Biotech Ltd. announced it received a notification from Nasdaq regarding its minimum bid price. The company is working to regain comp
• Purple Biotech Secures $50M ATM Offering — 6-K · Sep 19, 2025 Risk: medium
  On September 19, 2025, Purple Biotech Ltd. entered into an At The Market Offering Agreement (ATM Agreement) with H.C. Wainwright & Co., LLC. This agreement allo
• Purple Biotech Ltd. Updates Corporate Presentation — 6-K · Sep 16, 2025 Risk: low
  On September 15, 2025, Purple Biotech Ltd. released an updated corporate presentation titled "Purple Biotech Corporate presentation September 2025". This filing
• Purple Biotech Gets European Patent Intention for NT219 Combinations — 6-K · Sep 10, 2025 Risk: medium
  On September 10, 2025, Purple Biotech Ltd. announced it received an intention to grant a European patent for its NT219 drug when used in combination with immuno
• Purple Biotech Files 6-K with Warrant Forms and Press Release — 6-K · Sep 5, 2025 Risk: medium
  Purple Biotech Ltd. filed a Form 6-K on September 5, 2025, reporting on its activities for the month of September 2025. The filing includes exhibits such as the
• Purple Biotech Announces IM1240 Data — 6-K · Sep 4, 2025 Risk: medium
  On September 4, 2025, Purple Biotech Ltd. announced new data supporting the unique design of their tri-specific antibody, IM1240. This announcement was made in
• Purple Biotech Adds Novel TROP2 Antibody to CAPTN-3 Portfolio — 6-K · Sep 3, 2025 Risk: medium
  On September 3, 2025, Purple Biotech Ltd. announced the expansion of its CAPTN-3 portfolio with the addition of IM1305, a novel tri-specific antibody. This new
• Purple Biotech Reports Q2 2025 Financial Results — 6-K · Aug 6, 2025 Risk: low
  Purple Biotech Ltd. reported its second quarter 2025 financial results on August 6, 2025. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot,
• Purple Biotech CEO Updates Shareholders on H1 2025 Progress — 6-K · Jul 23, 2025 Risk: low
  On July 23, 2025, Purple Biotech Ltd. issued a press release detailing their progress in the first half of 2025. The CEO's letter to shareholders highlighted si
• Purple Biotech Updates Corporate Presentation — 6-K · Jul 10, 2025 Risk: low
  On July 10, 2025, Purple Biotech Ltd. released an updated corporate presentation titled "Purple Biotech Corporate presentation July 2025". This filing is a Repo
• Purple Biotech Highlights CAPTN-3 Platform at EACR 2025 — 6-K · Jun 23, 2025 Risk: low
  On June 23, 2025, Purple Biotech Ltd. announced significant advantages of its novel CAPTN-3 tri-specific antibody platform at the EACR 2025 Annual Conference. T
• Purple Biotech Starts Phase 2 Study for NT219 in Head and Neck Cancer — 6-K · Jun 17, 2025 Risk: medium
  On June 17, 2025, Purple Biotech Ltd. announced the initiation of a Phase 2 study for its drug candidate NT219. This study will evaluate NT219 in patients diagn
• Purple Biotech Reports Q1 2025 Financial Results — 6-K · May 21, 2025 Risk: low
  Purple Biotech Ltd. reported its first quarter 2025 financial results on May 21, 2025. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot, Is
• Purple Biotech Appoints New CFO — 6-K · May 12, 2025 Risk: low
  Purple Biotech Ltd. announced on May 12, 2025, the appointment of Shai Lankry as its new Chief Financial Officer. This appointment is detailed in a press releas
• Purple Biotech Ltd. Updates Company Presentation — 6-K · May 6, 2025 Risk: low
  On May 6, 2025, Purple Biotech Ltd. made available an updated Company Presentation on its website. This presentation is attached as Exhibit 99.1 to the 6-K fili
• Purple Biotech Reports Final CM24 Pancreatic Cancer Data — 6-K · Apr 30, 2025 Risk: medium
  Purple Biotech Ltd. announced final data from its Phase 2 study of CM24 in pancreatic cancer patients at the AACR 2025 Annual Meeting on April 30, 2025. The stu
• Purple Biotech Reports Positive NT219 Data — 6-K · Apr 28, 2025 Risk: medium
  On April 28, 2025, Purple Biotech Ltd. announced positive data from its Phase 1b study of NT219 in combination with nivolumab for patients with metastatic color
• Purple Biotech Ltd. Holds Annual Shareholder Meeting — 6-K · Apr 22, 2025 Risk: low
  Purple Biotech Ltd. announced the results of its Annual General Meeting of Shareholders held on April 22, 2025. The meeting took place at the company's offices
• Purple Biotech's NT219 Shows Promise Against Brain Metastasis — 6-K · Apr 16, 2025 Risk: medium
  On April 16, 2025, Purple Biotech Ltd. announced the publication of findings in the Neuro Oncology Journal. The study demonstrated the potential of their drug c
• Purple Biotech Ltd. Annual Meeting Adjourned — 6-K · Apr 15, 2025 Risk: medium
  Purple Biotech Ltd. held its Annual Meeting of Shareholders on April 15, 2025, which was convened and adjourned without any business being transacted. The compa
• Purple Biotech to Speak at Oncology Conference — 6-K · Apr 1, 2025 Risk: low
  Purple Biotech Ltd. announced on April 1, 2025, that it will participate in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference
• Purple Biotech to Present at 2025 AACR Meeting — 6-K · Mar 28, 2025 Risk: low
  On March 28, 2025, Purple Biotech Ltd. announced that three of its posters have been accepted for presentation at the 2025 American Association for Cancer Resea
• Purple Biotech Ltd. Updates Company Presentation — 6-K · Mar 18, 2025 Risk: low
  On March 18, 2025, Purple Biotech Ltd. made available an updated Company Presentation on its website. This presentation is attached as Exhibit 99.1 to the 6-K f
• Purple Biotech Ltd. Files 2024 Annual Report — 20-F · Mar 10, 2025 Risk: low
  Purple Biotech Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, formerly known as Kitov Pharma Ltd. and Kitov
• Purple Biotech Secures New US Patent for NT219 Combination Therapy — 6-K · Mar 5, 2025 Risk: low
  On March 5, 2025, Purple Biotech Ltd. announced it has been granted a new U.S. patent for its NT219 drug when used in combination with EGFR antibody therapy. Th
• Purple Biotech Sets April 15 AGM Date — 6-K · Feb 28, 2025 Risk: low
  Purple Biotech Ltd. announced its Annual General Meeting of Shareholders will take place on Tuesday, April 15, 2025, at 4:30 p.m. Israel time. The meeting will
• Purple Biotech Advances NT219 to Phase 2 for Head and Neck Cancer — 6-K · Feb 18, 2025 Risk: medium
  On February 18, 2025, Purple Biotech Ltd. announced the advancement of its drug candidate NT219 into a Phase 2 clinical trial for head and neck cancer. This mil
• Purple Biotech Partners with Mount Sinai for Antibody Platform — 6-K · Feb 3, 2025 Risk: medium
  On February 3, 2025, Purple Biotech Ltd. announced a research collaboration with the Icahn School of Medicine at Mount Sinai to advance their CAPTN-3 tri-specif
• Purple Biotech Ltd. Files 6-K on ATM Agreement — 6-K · Jan 6, 2025 Risk: low
  Purple Biotech Ltd. is filing a Form 6-K for January 2025, reporting on its Open Market Sale Agreement (ATM Agreement) with Jefferies LLC, entered into on June
• Purple Biotech Ltd. Updates Company Presentation — 6-K · Dec 6, 2024 Risk: low
  On December 6, 2024, Purple Biotech Ltd. announced it has made available an updated Company Presentation on its website. This presentation is attached as Exhibi
• Purple Biotech Closes $2.8M ADS Offering — 6-K · Dec 5, 2024 Risk: medium
  On December 5, 2024, Purple Biotech Ltd. announced the closing of a registered direct offering, successfully raising $2.8 million through the sale of American D
• Purple Biotech Files 6-K with Purchase Agreement Details — 6-K · Dec 4, 2024 Risk: low
  Purple Biotech Ltd. filed a Form 6-K on December 4, 2024, reporting a Securities Purchase Agreement and related documents. The filing includes exhibits such as
• Purple Biotech Raises $2.8M in Direct Offering — 6-K · Dec 3, 2024 Risk: medium
  On December 3, 2024, Purple Biotech Ltd. announced a registered direct offering to raise $2.8 million through the sale of American Depositary Shares. The compan
• Purple Biotech Reports Positive Phase 2 Pancreatic Cancer Study Results — 6-K · Dec 2, 2024 Risk: medium
  On December 2, 2024, Purple Biotech Ltd. announced positive final results from a Phase 2 study of its drug CM24 in patients with second-line pancreatic cancer.
• Purple Biotech Reports Q3 2024 Financial Results — 6-K · Nov 15, 2024 Risk: low
  Purple Biotech Ltd. announced its third quarter 2024 financial results on November 15, 2024. The company, formerly known as Kitov Pharma Ltd., is based in Rehov
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Purple Biotech Identifies Oncology Biomarker Linked to 79% PFS Reduction — 6-K · Nov 4, 2024 Risk: medium
  On November 4, 2024, Purple Biotech Ltd. announced the identification of a potential new serum biomarker for its lead oncology therapeutic candidate, CM24. This
• Purple Biotech Presents CAPTN-3 Data at EORTC-NCI-AACR — 6-K · Oct 25, 2024 Risk: medium
  On October 25, 2024, Purple Biotech Ltd. announced new data for its CAPTN-3 antibody platform, which targets tri-specific T cell and NK cell engagers. This pres
• Purple Biotech to Present CAPTN-3 Data at EORTC-NCI-AACR Symposium — 6-K · Oct 10, 2024 Risk: medium
  On October 10, 2024, Purple Biotech Ltd. announced it will present data for its Tri-Specific Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Mole
• Purple Biotech Ltd. Updates Company Presentation — 6-K · Oct 9, 2024 Risk: low
  On October 9, 2024, Purple Biotech Ltd. announced it has made an updated Company Presentation available on its website. This presentation is attached as Exhibit
• Purple Biotech Regains Nasdaq Bid Price Compliance — 6-K · Oct 2, 2024 Risk: medium
  On October 1, 2024, Purple Biotech Ltd. received confirmation from Nasdaq that it had regained compliance with the minimum bid price requirement. The company ha
• Purple Biotech Reports Positive Phase 2 Data for Candida — 6-K · Sep 18, 2024 Risk: medium
  On September 18, 2024, Purple Biotech Ltd. announced additional positive interim data from its Phase 2 study of its oncology therapeutic, Candida. The study is

Risk Profile

Risk Assessment: Of PPBT's 46 recent filings, 0 were flagged as high-risk, 22 as medium-risk, and 24 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Shai Lankry

Top Tags

biotech (17) · oncology (12) · drug-development (9) · shareholder-meeting (5) · financing (5) · company-update (5) · corporate-governance (4) · foreign-private-issuer (4) · corporate-update (4) · presentation (4)

Key Numbers

• ATM Offering Capacity: $50.0M — Maximum amount of ordinary shares Purple Biotech can sell under the agreement.
• Study Phase: Phase 1b — Indicates early-stage clinical trial
• Fiscal Year End: 20241231 — The period covered by the annual report.
• Filing Date: 20250310 — The date the annual report was submitted to the SEC.
• Capital Raised: $2.8M — Funds secured from the registered direct offering of American Depositary Shares.
• Registered Direct Offering: $2.8M — Capital raised by Purple Biotech Ltd.
• PFS Reduction: 79% — Associated with the identified biomarker when treated with CM24
• Minimum Bid Price: $1.00 — The threshold Purple Biotech needed to meet to regain compliance on Nasdaq.

Related Companies

PRPL

Frequently Asked Questions